NewsBenzingaEquillium、重篤な炎症性疾患の治療を目的としたEQ504の第1相臨床試験で、オーストラリアで最初の患者に投与を開始 Equillium、重篤な炎症性疾患の治療を目的としたEQ504の第1相臨床試験で、オーストラリアで最初の患者に投与を開始 Benzinga 2026.10.26 12:31 (GMT+0) Open on Benzinga Other news Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory NVIDIA Expands Vera CPU Racks for Scientific Computing Are Wall Street Analysts Predicting Lowe's Stock Will Climb or Sink? A whale accumulates 238,400 LINK from Binance in two days, worth about $2.2 million Google Warns ‘Era of Autonomous Attacks Has Arrived’ as United Airlines, JPMorgan Chase and Microsoft Grapple With Outages
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory
Google Warns ‘Era of Autonomous Attacks Has Arrived’ as United Airlines, JPMorgan Chase and Microsoft Grapple With Outages